PORTFOLIO
Hugel Pharma
-
YEAR
2017
-
STATUS
Exited
Hugel (KOSDAQ: 145020) is a publicly traded biopharmaceutical company in Korea that primarily focuses on the manufacturing and selling of botulinum toxin (BTX – widely known as Botox) and hyaluronic acid dermal fillers (HA Fillers).